To evaluate by ultrasonography the effect of chondroitin sulfate (CS) on synovitis in patients with knee osteoarthritis (KOA).
Synovitis occurs
in osteoarthritis, it is termed as inflammation of the synovial membrane. It
has been studied that administration of chondroitin sulfate (CS) on synovitis
significantly improves patients outcomes in patients with knee osteoarthritis
(KOA).
To evaluate by
ultrasonography the effect of chondroitin sulfate (CS) on synovitis in patients
with knee osteoarthritis (KOA). To collaborate in the understanding of the
biochemical mechanisms involved in the synovial inflammation process.
Randomized,
single-blind, controlled trial involving 70 patients with primary KOA treated
for 6 months with CS or acetaminophen (ACT). Evaluation of KOA status at
baseline, 6 weeks, 3 and 6 months included: ultrasonography to assess synovitis
(following the OMERACT expertise group definition), visual analogue scale and
Lequesne index to measure pain and function, and ELISA to quantify inflammatory
mediators in serum and synovial fluid.
Synovitis
presence was reduced by 50% in the CS group while a 123% increase was observed
in ACT group. Conversely, patients without initial synovitis and treated with
ACT reached 85.71% synovitis onset, but only 25% in CS group. Both therapies
improved articular function, but only CS resulted in significant pain
improvement at the end of the treatment. Changes in RANTES and UCN synovial
fluid concentration were associated with CS treatment.
Treatment with CS
had a sustained beneficial effect, preventing synovitis onset or reducing its
presence as well as reducing KOA symptoms. ACT ameliorated clinical symptoms
but had no effect on inflammation. The CS anti-inflammatory effect could be
related to the observed changes in RANTES and UCN concentration.
Med Clin (Barc). 2017 Jul 7;149(1):9-16
Effect of chondroitin sulfate on synovitis of knee osteoarthritic patients
Tío L et al.
Comments (0)